| INTRODUCTION
Clostridium difficile is a leading cause of infectious diarrhea, with a reported incidence rate of 7 cases per 10 000 patient-bed days in Europe.
1 Solid organ transplant (SOT) recipients are at higher risk for CDI than the general population, due to numerous risk factors including severe underlying diseases, immunosuppression, recent surgery, antibiotic treatment, ganciclovir prophylaxis, gastric acid suppression, and prolonged hospital stay. [2] [3] [4] [5] A recently published meta-analysis in SOT recipients reported an overall prevalence of 7.4%. 6 The clinical spectrum of CDI ranges from asymptomatic colonization to fulminant pseudomembranous colitis. Knowledge about the severity of CDI and the impact on graft function in SOT is scarce and contradictory; while some authors have described a worse outcome of CDI in SOT recipients, 2, 4, 5, 7, 8 a recent Spanish cohort study and two US studies reported a good prognosis of CDI in SOT recipients. [9] [10] [11] These aspects are important, as newer treatment guidelines for CDI stratify according to the clinical severity of disease, emphasizing the reduction of recurrence of CDI. 12, 13 Indeed, whereas both oral metronidazole and vancomycin were equally effective for treatment of mild CDI, response rates were superior for vancomycin in patients with severe CDI in a randomized trial.
14 Accordingly, the recently updated guidelines of the
European Society for Clinical Microbiology and Infectious Diseases
(ESCMID) and the latest US American guidelines recommend as first option oral metronidazole for patients with nonsevere and oral vancomycin for severe CDI. 12, 13 Fidaxomicin achieved significantly lower rates of recurrence of CDI in two clinical trials. 15, 16 Accordingly, the ESCMID guidelines recommend the use of fidaxomicin for patient at risk for recurrent CDI.
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Our main objective was to determine the outcome of CDI in SOT recipients. Secondary aims were to describe incidence and clinical severity, and to identify risk factors for CDI within this population.
| METHODS

| Patients and study design
The Swiss Transplant Cohort Study (STCS) is an observational national cohort, enrolling all SOT recipients followed at 6 Swiss university centers. Details on data definitions and the cohort structure have been published previously. 17, 18 For the present study, all SOT recipients prospectively enrolled in the STCS between May 2008
and August 2013 with written informed consent were included.
The protocol was approved by the ethics committee of all participating centers. Patient's data were collected in the STCS database at enrollment, 6 and 12 months, and yearly after transplantation on standardized electronic case report forms (eCRFs 
| Definitions
To ensure homogeneous assessment of the infectious disease events in the STCS, specifically trained infectious diseases specialists at each center record the occurrence of infectious events using standardized definitions. 
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We defined graft loss as follows: recurrence of insulin-dependence following pancreas transplant, dialysis post renal transplantation, retransplantation post heart, liver, or lung transplantation. All-cause mortality, and mortality assumed to be related to CDI were collected separately. cause of an excessively large confident interval. We also investigated the probability for recurrent CDI episodes using logistic regression models without further risk adjustment.
| Statistical analysis
We further performed Cox proportional hazard (PH) models to evaluate the effect of CDI on the occurrence of graft loss and death.
We applied noninformative censoring about the outcome (death, graft loss). CDI was considered as a time-dependent risk factor in time-to-event analyses. In addition to CDI, we included baseline and time-dependent risk factors (surgical complications, medical problems, rejection, and relevant infections) in the graft loss analysis ( Table   5 ). The PH assumption was verified by plotting Schoenfeld residuals to visualize the effect over time. When the PH assumption was violated, but the effect strong and without change of the direction, no restrictions were included, and the interpretation was not hampered.
All statistical analyses were performed using the statistical software R (version 3.2.0; R Foundation for Statistical Computing, Vienna, Austria).
| RESULTS
| Population characteristics and incidence of CDI
During the observation period, 2400 SOTs were performed in Switzerland. After exclusion of combined transplants and patients who did not sign the informed consent, we included 2158 patients (1261 kidney, 454 liver, 224 lung, 164 heart, and 55 kidney-pancreas recipients) in the present study. Within the study population, we identified 87 patients (cases) with 102 proven CDI episodes corresponding to a crude incidence of 4.0%. CDI was observed in 35 kidney, 23 liver, 22 lung, and 7 heart recipients ( Table 1 ). The cumu- 
| Risk factors for CDI development
In univariate analysis, infections, especially proven bacterial infections, anti-infective therapy, antibiotic therapy, all ß-lactams and quinolones, and hospitalization in the 3 months preceding the event were associated with the development of CDI ( 95% CI 2.03-10.00, P < .001) during the 3 months preceding the event remained significantly associated with CDI development.
| Treatments
Seventy-one cases (83.5%) were treated with metronidazole for a median duration of 11 days (IQR 10-15), 10 cases (11.8%) were treated with oral vancomycin for a median duration of 11 days (IQR 10-13) and 4 cases (4.7%) received a combined treatment with metronidazole and vancomycin (Table 3) . Two cases with a mild course of CDI recovered spontaneously without any treatment. Recurrent CDI was treated by metronidazole in 9, vancomycin in 2 cases, and combination therapy in 3 cases.
| Clinical severity and recurrence
Sixty-five of 87 cases (74.7%) had a mild to moderate, 19 (21.8%) a severe, and 3 (3.4%) a severe complicated course of CDI (Table 3) . (Table 3) . 49 years, P < .001) and patients transplanted for heart, liver, and lung had a higher risk of death compared to kidney recipients (P < .001) ( Table 6 ). This was confirmed in multivariable analysis.
| Outcome analysis
CDI increased mortality in univariate analysis (HR 2.31; 95% CI 1.33-3.99, P = .003); however, this effect was no longer significant in the multivariable model (HR 1.63, 95% CI 0.94-2.83, P = .085) (Table 6 ).
In univariate analysis for graft loss, baseline recipient characteristics (age, gender, transplant) showed no significant effects (P > .05) ( Table 6 ). In contrast, the occurrence of CDI was associated with graft loss (HR 3.72, 95% CI 1.92-7.20, P < .001). To confirm T A B L E 3 Clinical variables and course of patients with single and multiple CDI events this effect, we accounted for further time-dependent risk factors potentially associated with graft loss. These included general and transplant-specific surgical complications, medical problems, rejection, and both systemic and transplant specific infections (Table 5) .
Combined surgical complications, medical problems, relevant infections, as well as both bacterial and fungal infections analyzed alone or in combination, were all significantly associated with graft loss in univariate analyses (Table 6 (Table 6 ).
| DISCUSSION
We report the results of a nationwide study of 87 cases of Clostridium difficile infections among 2158 SOT recipients in the STCS. We identified and confirmed preceding infection and antibiotic use as risk factors for CDI. We showed that despite most episodes being clinically benign, CDI was associated with a 2.2-fold increased risk of graft loss.
The crude incidence of CDI in our prospectively evaluated cohort including >90% of all Swiss SOT recipients was 4% corresponding to an infection rate of 0.47 per 10 000 patient-days. This incidence is low as compared to previous reports, including a meta-analysis comprising 30 studies reporting an overall incidence of 7.4% CDI in SOT recipients. 6 Methodological differences in calculating the occurrence of CDI in SOT might explain such differences. Of note the incidence of CDI in the general Swiss population in hospitals compares to other European countries (4.8 cases vs 4.1 cases per 10 000 patients-days, respectively). 21 In accordance with earlier reports, lung recipients had the highest incidence rate as well as the earliest occurrence after transplantation. 4, 5, 9, 22 Consequently, some authors have suggested to implement metronidazole as prophylaxis early after lung transplantation.
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Of major importance is our observation that despite low clinical severity and good therapeutic response, CDI in SOT recipients was associated with an increased risk of graft loss. An impact on graft function has been suggested previously for noninfectious diarrhea, 24 but to our knowledge was never associated with CDI. The therapeutic efficacy of fecal transplantation in the treatment of CDI highlights the importance of CDI as a marker of intestinal dysbiosis. 25, 26 It is likely, that whereas the immune dysregulation is the initial insult leading to intestinal dysbiosis in SOT recipients, potentially further worsened by antibiotic treatments, 27 CDI aggravates this intestinal microbial imbalance.
Inflammation associated with CDI could also provoke graft rejection via innate immune mechanisms. In such a scenario, dysbiosis or the C. difficile itself could enhance helper T cells responses, thereby affecting the graft. However, whether CDI itself or this exacerbated intestinal dysbiosis increases the risk of graft loss is impossible to distinguish at this point. Diarrhea and intestinal dysbiosis could both interfere with adequate absorption and/or the metabolism of immunosuppressive agents, thereby increasing the risk for graft failure. The higher rates of graft loss and death in CDI cases could also be an indirect marker of sicker patients and an unfavorable posttransplantation course, as evidenced by the higher numbers of infections and antibiotic administration in cases compared to controls in this study, rather than a direct effect of the CDI. In line with this hypothesis is the recent report describing a higher number of organ specific complications among SOT recipients.
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Further prospective studies, analyzing CDI and microbiome changes, as well as immune responses will be needed to decipher the type of association between CDI and graft loss, and its underlying mechanisms. developing CDI. Still, as previously noted, 25% of patients with CDI had not received antibiotics in the last 3 months. 27 In these cases, the development of CDI has been suggested to be linked to immune dysfunction in SOT recipients. 27 As is the case for the Spanish cohort, we found no association with induction therapy or with different immunosuppression regimens.
T A B L E 5 Definitions and description of time-dependent risk factors
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In our study, 75% of CDI episodes were mild to moderate, 3 cases (3.4%) had a severe complicated course, and no patient required a surgical intervention or died due to CDI. This is a more benign course as compared to previously published data reporting 5.3% complicated cases. 6 The severity of CDI has been shown to depend on the presence of circulating hyper-virulent strains such as ribotype 027. 29 It is likely that the favorable outcome in the present report may be linked to a low prevalence of hypervirulent ribotypes in Switzerland. 30 In correlation with the low clinical severity, most of our cases (83.5%) were treated with metronidazole for a medium duration of 11 days according to current guidelines. 27 CDI recurred in 16.1% cases, less frequently as compared to 19.7% reported in the literature. 6 In the absence of genotyping, differentiation between relapses and reinfections was not possible. However, 59%
of the recurrent CDI episodes occurred within 8 weeks after the first, suggesting that these second events were relapses rather than reinfections.
Our study has some limitations. The CDI incidence rate may be underestimated, especially for CDI episodes that could have occurred outside the transplant centers. However, most CDIs occurred early after transplant when SOT recipients were in close contact with the transplant center, and we suppose that only very few events have been missed. The use of different diagnostic tests, including culture, detection of antigens and Clostridium difficile-toxin, by enzyme immune assay and PCR might also have affected incidence rates. Despite our study being one of the largest series of CDI in SOT recipients published to date, 6 the number of CDI per transplant remained small and required pooling of specific risk factors in the multivariable analysis.
The strength of our study remains the comprehensive nationwide enrollment of all Swiss SOT recipients, which guaranties highly representative data of the real-life situation in Switzerland.
In conclusion, preceding bacterial infections and antibiotic treat- 
